Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas

被引:65
作者
Meier, Cecile [1 ]
Hoeller, Sylvia [1 ]
Bourgau, Caroline [1 ]
Hirschmann, Petra [1 ]
Schwaller, Juerg [2 ]
Went, Philip [1 ]
Pileri, Stefano A. [3 ]
Reiter, Andreas [4 ]
Dirnhofer, Stephan [1 ]
Tzankov, Alexandar [1 ]
机构
[1] Univ Basel, Dept Pathol, CH-4031 Basel, Switzerland
[2] Univ Basel, Dept Res, CH-4031 Basel, Switzerland
[3] Univ Bologna, St Orsola Hosp, Dept Hematol & Oncol Sci L & A Seragnoli, Sch Med,Haematopathol Sect, Bologna, Italy
[4] Univ Heidelberg, Fac Clin Med Mannheim, Dept Hematol & Oncol, D-6800 Mannheim, Germany
关键词
Janus kinase 2; pSTAT3; pSTAT5; FISH; gains; 9p24; lymphoma; B-CELL LYMPHOMA; CLASSICAL HODGKIN LYMPHOMA; TYROSINE KINASE JAK2; MYELOPROLIFERATIVE DISORDERS; HEMATOLOGICAL MALIGNANCIES; PCM1-JAK2; FUSION; T(8/9) TRANSLOCATION; FOLLICULAR LYMPHOMA; ACTIVATING MUTATION; STAT3;
D O I
10.1038/modpathol.2008.207
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The Janus kinase 2 (JAK2)-signal transducers and activators of transcription (STAT) pathway plays an important role in hematological malignancies. Mutations and translocations of the JAK2 gene, mapped at 9p24, lead to constitutive activation of JAK2 and its downstream targets. The presence of JAK2 mutations in lymphomas has been addressed in larger cohorts, but there are little systemic data on numerical and structural JAK2 aberrations in lymphoid neoplasms. To study the molecular epidemiology of these aberrations and the consecutive activation of the JAK2-STAT pathway in lymphomas, we examined 527 cases, covering the most common entities, in a tissue microarray by fluorescent in situ hybridization with breakable JAK2 probes, and immunohistochemistry for phosphorylated JAK2 (pJAK2) and its preferred downstream pSTAT3 and pSTAT5. 9p24 gains were detected in 6/17 (35%) primary mediastinal B-cell lymphomas (PMBCLs), 25/77 (33%) Hodgkin's lymphomas (HLs), 3/16 (19%) angioimmunoblastic T-cell lymphomas (AILTs) and 1/5 ALK1(+) anaplastic large cell lymphomas (ALCLs); breaks were observed only in three cases. pJAK2 expression was most prevalent in PMBCL, peripheral T-cell lymphomas and HL. pSTAT3 predominated in ALCLs, HLs, AILTs, PMBCLs and peripheral T-cell lymphomas. pSTAT5 expression was detected frequently in follicular lymphomas, diffuse large B-cell lymphomas and AILTs. 9p24 gains correlated with increased proportions of tumor cells expressing pJAK2 (P=0.002) and pSTAT3 (P=0.001). In follicular lymphomas, concomitant expression of pJAK2 and pSTAT5 was linked to better prognosis, whereas expression of pSTAT3 in nongerminal center-like diffuse large B-cell lymphomas could identify a patient group with an inferior outcome. Our findings stress that despite the rarity of activating JAK2 mutations in lymphomas, JAK2 is recurrently targeted by numerical, and rarely by structural, genetic aberrations in distinct lymphoma subtypes and that JAK2-STAT pathway may play a role in lymphomagenesis.
引用
收藏
页码:476 / 487
页数:12
相关论文
共 40 条
  • [11] Jak2: normal function and role in hematopoietic disorders
    Ihle, James N.
    Gilliland, D. Gary
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2007, 17 (01) : 8 - 14
  • [12] Jaffe E.S., 2001, PATHOLOGY GENETICS T, V3
  • [13] Joos S, 2000, CANCER RES, V60, P549
  • [14] The role of Janus kinases in haemopoiesis and haematological malignancy
    Khwaja, Asim
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (04) : 366 - 384
  • [15] A gain-of-function mutation of JAK2 in myeloproliferative disorders
    Kralovics, R
    Passamonti, F
    Buser, AS
    Teo, S
    Tiedt, R
    Passweg, JR
    Tichelli, A
    Cazzola, M
    Skoda, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) : 1779 - 1790
  • [16] JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas
    Lee, JW
    Soung, YH
    Kim, SY
    Nam, SW
    Park, WS
    Lee, JY
    Yoo, NJ
    Lee, SH
    [J]. LEUKEMIA & LYMPHOMA, 2006, 47 (02) : 313 - 314
  • [17] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    Levine, RL
    Wadleigh, M
    Cools, J
    Ebert, BL
    Wernig, G
    Huntly, BJP
    Boggon, TJ
    Wlodarska, L
    Clark, JJ
    Moore, S
    Adelsperger, J
    Koo, S
    Lee, JC
    Gabriel, S
    Mercher, T
    D'Andrea, A
    Fröhling, S
    Döhner, K
    Marynen, P
    Vandenberghe, P
    Mesa, RA
    Tefferi, A
    Griffin, JD
    Eck, MJ
    Sellers, WR
    Meyerson, M
    Golub, TR
    Lee, SJ
    Gilliland, DG
    [J]. CANCER CELL, 2005, 7 (04) : 387 - 397
  • [18] STATs: Transcriptional control and biological impact
    Levy, DE
    Darnell, JE
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (09) : 651 - 662
  • [19] Phosphorylation state-specific antibodies applications in investigative and diagnostic pathology
    Mandell, JW
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (05) : 1687 - 1698
  • [20] Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene
    Mark, Hon Fong L.
    Sotomayor, Edgar A.
    Nelson, Marilu
    Chaves, Fernando
    Sanger, Warren G.
    Kaleem, Zahid
    Caughron, Samuel K.
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2006, 81 (03) : 217 - 223